< Back to previous page
Researcher
Johan Maertens
- Disciplines:Biochemistry and metabolism, Microbiology, Systems biology, Laboratory medicine, Medical biochemistry and metabolism
Affiliations
- Laboratory of Clinical Microbiology (Division)
Member
From1 Oct 2014 → Today - Department of Microbiology, Immunology and Transplantation (Department)
Member
From1 Oct 2013 → 30 Sep 2014 - Woman and Child (Division)
Member
From1 Apr 2013 → 30 Sep 2013
Projects
1 - 10 of 11
- Insights in febrile neutropenia (SAFE study) and clinical and translational insights in (invasive) mold infections and mycology, with the focus on Hematologic patients.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimization and validation of collateral sensitivity based alternative treatment strategies for multidrug resistant CandidemiaFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- SAFE study: a randomized non-inferiority trialFrom1 Oct 2022 → TodayFunding: Foundations, funds and other with scientific goal
- Improving prevention and treatment strategies concerning opportunistic infections in immunocompromised hematologic patientsFrom14 Sep 2020 → TodayFunding: Foundations, funds and other with scientific goal
- Clonal evolution and biology of co-operative oncogenic events in acute lymphoblastic leukemia.From1 Oct 2018 → 30 Sep 2023Funding: Fund Recuperation Fiscal Exemption
- Fast diagnosis of opportunistic respiratory infections trough exhaled breath analysisFrom1 Oct 2017 → 30 Sep 2020Funding: FWO Applied Biomedical Research (TBM)
- Triazole-resistance in Aspergillus fumigatus: evolving epidemiology and influence on disease progression.From15 Mar 2017 → 2 Dec 2021Funding: BOF - doctoral mandates, BOF - Doctoral projects
- Faster to the fungus: rapid diagnostic and prognostic tests for invasive fungal diseasesFrom1 Aug 2016 → 9 Oct 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Rethinking 'Care after Cure' in allogeneic hematopoietic stem cell transplantation using e-Health and patient reported outcomesFrom1 Sep 2015 → 14 Nov 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Assessment of the impact of emerging azole resistance mechanisms on treatment response of invasive pulmonary aspergillosis using non-invasive imaging in experimental Aspergillus infection models.From1 Jan 2015 → 31 Dec 2018Funding: FWO research project (including WEAVE projects)
Publications
21 - 30 of 536
- The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia(2023)
Authors: Johan Maertens
- Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Societe Francophone De Greffe De Moelle Et Therapie Cellulaire (SFGM-TC)(2023)
Authors: Johan Maertens
- Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT(2023)
Authors: Johan Maertens
- A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy(2023)
Authors: Johan Maertens
- Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)(2023)
Authors: Johan Maertens
- Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party(2023)
Authors: Johan Maertens
- AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ADULTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION. A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT(2023)
Authors: Johan Maertens
Pages: 167 - 168 - GVHD PROPHYLAXIS INCORPORATING METHOTREXATE IN ALLO-HCT FOR CHRONIC MYELOID MALIGNANCIES AND SAML: A RETROSPECTIVE ANALYSIS FROM THE CMWP OF THE EBMT(2023)
Authors: Johan Maertens
Pages: 66 - 67 - Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT(2023)
Authors: Johan Maertens
Pages: 1197 - 1202 - RISK FACTORS AND PROGNOSIS OF NOCARDIA INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN INFECTIOUS DISEASES WORKING PARTY AND FRANCO-BELGIAN NOCARDIA STUDY GROUP CASE-CONTROL STUDY(2023)
Authors: Johan Maertens
Pages: 401 - 402